Aberdeen

Aberdeen Therapeutics is a biotechnology company focused on developing next-generation small molecule therapeutics for the treatment of hormone-dependent cancers, particularly prostate and breast cancer. Spun out from the University of Aberdeen, the company leverages deep expertise in nuclear receptor signaling to target the N-terminal domain of the androgen receptor. Their approach aims to overcome resistance mechanisms common in existing endocrine therapies, providing new options for patients with advanced disease. The company is currently advancing its lead programs through pre-clinical development, focusing on intrinsically disordered protein regions as therapeutic targets.